L-铃兰氨酸 | 2517-04-6

• 物质功能分类: 生物化工 - 常见氨基酸及蛋白质类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-铃兰氨酸
• 中文别名: 氮杂环丁烷-2-羧酸；2-氮杂环丁烷甲酸；2-吖丁啶羧酸
• 英文名称: Azetidine-2-carboxylic acid
• 英文别名: azetidin-1-ium-2-carboxylate
• CAS: 2517-04-6
• 化学式: C₄H₇NO₂
• mdl: MFCD00066660
• 分子量: 101.105
• InChiKey: IADUEWIQBXOCDZ-UHFFFAOYSA-N

物化性质

• 熔点：
  217°C (rough estimate)
• 沸点：
  189.47°C (rough estimate)
• 密度：
  1.2245 (rough estimate)
• 溶解度：
  超声处理可轻微溶于甲醇和水
• 物理描述：
  Solid
• 稳定性/保质期：
  - 存在于烟叶中。 - 对无机酸不够稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Azetidine-2-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H318: Causes serious eye damage
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Azetidine-2-carboxylic acid
CAS number: 2517-04-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H7NO2
Molecular weight: 101.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Azetidine-2-carboxylic acid 是脯氨酸的一种非蛋白原氨基酸同系物，常见于甜菜中。在许多物种（包括人类）中，它可能会错误地掺入蛋白质中代替脯氨酸，具有致毒和致畸作用。

体外研究

在体外实验中，Azetidine-2-carboxylic acid (375-500 μg/天) 被发现能够被鸡胚胎软骨细胞用于合成胶原蛋白。

反应信息

• 作为反应物：
  描述：

  L-铃兰氨酸 在 氯化亚砜 、 碳酸氢钠 作用下， 以 乙醇 为溶剂， 生成 氮杂丁烷-2-羧酸乙酯
  参考文献：
  名称：

  NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS

  摘要：

  本发明涉及一种具有化学式1、2或3的化合物：其中A为N或—CR0—，其中R0为氢、C1-C6直链或支链烷基等，Z为—CRe—或—N—，其中Re为氢、C1-C6直链或支链烷基等；R1为氢、C1-C6直链或支链烷基等；R2独立地为氢或C1-C6直链或支链烷基；R3和R4独立地为氢、C1-C6直链或支链烷基等；R5和R6独立地为氢或C1-C6直链或支链烷基等；R8为氢、C1-C6直链或支链烷基等；R9和R10独立地为氢或C1-C6直链或支链烷基等；Q为—CO—、—(CH2)q—、—(CHRs)q—或(CRsRt)q—，其中Rs和Rt独立地为C1-C6直链或支链烷基、芳基、烷基芳基、杂芳基或烷基杂芳基；其中q为0、1、2或3；n为0、1、2、3、4或5；或其药学上可接受的盐，以及含有这种化合物的组合物；以及这种化合物在治疗各种疾病中的用途，特别是那些受雄激素受体影响或介导的疾病。

  公开号：

  US20140155390A1
• 作为产物：
  描述：

  苄基N-二苯基甲基-2-吖丁啶羧酸酯 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 反应 6.0h， 生成 L-铃兰氨酸
  参考文献：
  名称：

  Enantioselective catalytic reductions of ketones with new four membered oxazaborolidines: Application to (S)-tetramisole

  摘要：

  Enantioselective catalytic reduction of ketones with both the enantiomers of new four membered oxazaborolidines is described.

  DOI：

  10.1016/s0957-4166(00)82184-9

文献信息

• [EN] HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE<br/>[FR] PYRROLOPYRIDINES À SUBSTITUTION HÉTÉROCYCLYLE UTILISÉES EN TANT QU'INHIBITEURS DE LA KINASE CDK12
  申请人：UNIV NOTTINGHAM

  公开号：WO2019058132A1

  公开（公告）日：2019-03-28

  This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular,the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.

  这项发明涉及抑制CDK12激酶的化合物。这些化合物可用于治疗由CDK12激酶介导的疾病，包括1型肌强直性营养不良（DM1）和其他由RNA重复扩展转录物引起的疾病。特别是，该发明涉及公式（I）的化合物，或其药用可接受的盐或N-氧化物，其中R1a, R2, R3, R4a, R4b和R4c按本文定义。
• Amino acid derivatives
  申请人：AstraZeneca AB

  公开号：US06337343B1

  公开（公告）日：2002-01-08

  There is provided amino acid derivatives of formula I, wherein p, q, R1, R2, R3, R4, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供的是公式I的氨基酸衍生物，其中p、q、R1、R2、R3、R4、Y、n和B具有本说明书中给出的含义，它们可用作胰蛋白酶样蛋白酶（如凝血酶）的竞争性抑制剂，特别是在需要抑制凝血酶的情况（例如血栓形成）的治疗中，或者作为抗凝剂。
• BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
  申请人：Singh Jasbir

  公开号：US20090136473A1

  公开（公告）日：2009-05-28

  The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: A particular embodiment is

  本发明涉及一类含有至少一个进一步环的联苯化合物的属。这些化合物是PDE4抑制剂，用于治疗和预防中风、心肌梗死和心血管炎症性疾病和紊乱。这些化合物具有一般式Ia、Ib、Ic或Id： 一个特定的实施例是
• 2-aminopyridines containing fused ring substituents
  申请人：——

  公开号：US20010049379A1

  公开（公告）日：2001-12-06

  The present invention relates to 2-aminopyridine derivatives of the formula 1 wherein G, R 1 and R 2 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

  本发明涉及公式1中定义的G、R1和R2的2-氨基吡啶衍生物，其表现为一氧化氮合酶（NOS）抑制剂的活性，以及含有它们的药物组合物，并且它们在治疗和预防中枢神经系统和其他疾病中的应用。
• Imidazodiazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US05665718A1

  公开（公告）日：1997-09-09

  The invention relates to compounds of the formula ##STR1## wherein A together with the two carbon atoms denoted by .alpha. and .beta. is one of the residues ##STR2## Q is one of the residues ##STR3## R.sup.1 and R.sup.2 each independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower hydroxyalkyl, lower alkoxy-lower alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, (C.sub.3 -C.sub.6)-cycloalkyl-lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl or aryl-lower alkyl or together with the nitrogen atom are a 5- to 8-membered membered heterocycle optionally containing a further hetero atom or a fused benzene ring, R.sup.3 is hydrogen and R.sup.4 is lower alkyl or R.sup.3 and R.sup.4 together are dimethylene or trimethylene and R.sup.5 and R.sup.6 each independently are hydrogen, halogen, trifluoromethyl, lower alkoxy or nitro, the compounds of formula I having the (S) configuration with reference to the carbon atom denoted by .gamma. when R.sup.3 and R.sup.4 together are dimethylene or trimethylene, and pharmaceutically acceptable acid addition salts thereof. These compounds and salts have pronounced anxiolytic, anticonvulsant, muscle relaxant and sedative-hypnotic properties.

  本发明涉及具有以下公式的化合物：##STR1## 其中A与标记为α和β的两个碳原子共同构成##STR2##中的一个残基；Q是##STR3##中的一个残基；R1和R2各自独立地为氢、低级烷基、低级烯基、低级炔基、低级羟基烷基、低级烷氧基-低级烷基、(C3-C6)-环烷基、(C3-C6)-环烷基-低级烷基、氨基-低级烷基、低级烷基氨基-低级烷基、二低级烷基氨基-低级烷基或芳基-低级烷基，或者与氮原子共同形成一个含有另外一种杂原子或一个融合的苯环的5至8成员的杂环；R3是氢，R4是低级烷基，或者R3和R4共同是亚甲基或三亚甲基；R5和R6各自独立地为氢、卤素、三氟甲基、低级烷氧基或硝基；当R3和R4共同是亚甲基或三亚甲基时，相对于标记为γ的碳原子，本发明的公式I化合物具有(S)构型，以及它们的药物可接受的酸加成盐。这些化合物和盐具有显著的抗焦虑、抗惊厥、肌肉松弛和镇静催眠性质。

表征谱图